Gilead Halts Phase 3 Remdesivir Study in High-Risk Nonhospitalized COVID-19 Patients

Gilead Sciences has ended a phase 3 study evaluating an intravenous formulation of its antiviral Veklury (remdesivir) in high-risk nonhospitalized COVID-19 patients.

The decision to end the trial was not due to efficacy or safety concerns, but because Gilead does not believe that “a multiple-day IV infusion treatment that requires administration in a healthcare setting addresses an unmet need for nonhospitalized patients.”

Patients already participating in the study will continue to be assessed, the company said, adding that it is currently developing an experimental inhaled formulation of remdesivir.